If SARS-CoV-2’s “hijack” of ACE2 is what initiates microvascular inflammation, leading to ARDS and multiorgan failure in fatal COVID-19 infections, statin intervention targeted early in the inflammatory cascade should ameliorate the detrimental pathogenic mechanisms that underlie ARDS, cytokine storm, and vascular collapse. This evidence concerns the gene ACE2 and acute respiratory distress syndrome.